[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b17cbde92811494bd3d52c378f94f10061ba7e876f9d3e731d7327f4f31daf05",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738773420,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 132576774,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b17cbde92811494bd3d52c378f94f10061ba7e876f9d3e731d7327f4f31daf05"
    }
  },
  {
    "ts": null,
    "headline": "Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)",
    "summary": "Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising partnerships. Click for my CRSP stock update.",
    "url": "https://finnhub.io/api/news?id=8e4ead3b5ec7fa74154cd7fbe8b49b72ff4aad1233f823d51fcf67060a99d474",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738770506,
      "headline": "Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)",
      "id": 132567872,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316503044/image_1316503044.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising partnerships. Click for my CRSP stock update.",
      "url": "https://finnhub.io/api/news?id=8e4ead3b5ec7fa74154cd7fbe8b49b72ff4aad1233f823d51fcf67060a99d474"
    }
  },
  {
    "ts": null,
    "headline": "Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?",
    "summary": "On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).",
    "url": "https://finnhub.io/api/news?id=fac579c60cb7ded21ab0ae16cb97520ceb561c707953989f4e5df4b57b6f9846",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738767240,
      "headline": "Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?",
      "id": 132631699,
      "image": "https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).",
      "url": "https://finnhub.io/api/news?id=fac579c60cb7ded21ab0ae16cb97520ceb561c707953989f4e5df4b57b6f9846"
    }
  },
  {
    "ts": null,
    "headline": "Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.",
    "url": "https://finnhub.io/api/news?id=1eb0dbb284e570915301b52faf7e95e72851d69894eab8f1e4fceff9ecbea91f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738764925,
      "headline": "Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics",
      "id": 132631700,
      "image": "https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.",
      "url": "https://finnhub.io/api/news?id=1eb0dbb284e570915301b52faf7e95e72851d69894eab8f1e4fceff9ecbea91f"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Growth Portfolios Q4 2024 Commentary",
    "summary": "Performance was supported in the quarter by AI-indexed semiconductor and software provider Broadcom, along with a cohort of disruptors. Read more here.",
    "url": "https://finnhub.io/api/news?id=c9fafe55af9968c5fff0f9de4be882738f07d01c01f0ff6eb7bb997d3221ceb4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738743300,
      "headline": "ClearBridge Growth Portfolios Q4 2024 Commentary",
      "id": 132562056,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1061700868/image_1061700868.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Performance was supported in the quarter by AI-indexed semiconductor and software provider Broadcom, along with a cohort of disruptors. Read more here.",
      "url": "https://finnhub.io/api/news?id=c9fafe55af9968c5fff0f9de4be882738f07d01c01f0ff6eb7bb997d3221ceb4"
    }
  }
]